Inmune Bio Stock Earnings Per Share
| INMB Stock | USD 11.29 0.45 4.15% |
INmune Bio fundamentals help investors to digest information that contributes to INmune Bio's financial success or failures. It also enables traders to predict the movement of INmune Stock. The fundamental analysis module provides a way to measure INmune Bio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to INmune Bio stock.
INmune | Earnings Per Share |
INmune Bio Company Earnings Per Share Analysis
INmune Bio's Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Current INmune Bio Earnings Per Share | (1.67) X |
Most of INmune Bio's fundamental indicators, such as Earnings Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, INmune Bio is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
INmune Earnings Per Share Driver Correlations
Understanding the fundamental principles of building solid financial models for INmune Bio is extremely important. It helps to project a fair market value of INmune Stock properly, considering its historical fundamentals such as Earnings Per Share. Since INmune Bio's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of INmune Bio's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of INmune Bio's interrelated accounts and indicators.
Click cells to compare fundamentals
Earnings per Share is one of the most critical measures of the firm's current share price and is used by investors to determine the overall company profitability, especially when compared to the EPS of similar companies.
| Competition |
INmune Common Stock Shares Outstanding
Common Stock Shares Outstanding |
|
According to the company disclosure, INmune Bio has an Earnings Per Share of -1.67 times. This is 119.95% lower than that of the Biotechnology sector and 65.14% lower than that of the Health Care industry. The earnings per share for all United States stocks is 153.53% higher than that of the company.
INmune Earnings Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses INmune Bio's direct or indirect competition against its Earnings Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of INmune Bio could also be used in its relative valuation, which is a method of valuing INmune Bio by comparing valuation metrics of similar companies.INmune Bio is currently under evaluation in earnings per share category among related companies.
INmune Bio Current Valuation Drivers
We derive many important indicators used in calculating different scores of INmune Bio from analyzing INmune Bio's financial statements. These drivers represent accounts that assess INmune Bio's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of INmune Bio's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 59.6M | 206.4M | 164.5M | 113.7M | 202.5M | 101.6M | |
| Enterprise Value | 52.8M | 184.6M | 105.0M | 76.8M | 177.1M | 185.9M |
INmune Fundamentals
| Return On Equity | -0.61 | ||||
| Return On Asset | -0.27 | ||||
| Operating Margin | (299.25) % | ||||
| Current Valuation | 178.91 M | ||||
| Shares Outstanding | 18.77 M | ||||
| Shares Owned By Insiders | 33.94 % | ||||
| Shares Owned By Institutions | 13.19 % | ||||
| Number Of Shares Shorted | 1.5 M | ||||
| Price To Earning | (7.51) X | ||||
| Price To Book | 4.91 X | ||||
| Price To Sales | 1,208 X | ||||
| Revenue | 155 K | ||||
| Gross Profit | 374 K | ||||
| EBITDA | (29.74 M) | ||||
| Net Income | (30.01 M) | ||||
| Cash And Equivalents | 61.21 M | ||||
| Cash Per Share | 3.41 X | ||||
| Total Debt | 10.44 M | ||||
| Debt To Equity | 0.22 % | ||||
| Current Ratio | 30.87 X | ||||
| Book Value Per Share | 2.08 X | ||||
| Cash Flow From Operations | (11.98 M) | ||||
| Short Ratio | 14.76 X | ||||
| Earnings Per Share | (1.67) X | ||||
| Target Price | 19.67 | ||||
| Number Of Employees | 11 | ||||
| Beta | 1.95 | ||||
| Market Capitalization | 211.97 M | ||||
| Total Asset | 57 M | ||||
| Retained Earnings | (121.02 M) | ||||
| Working Capital | 21.48 M | ||||
| Current Asset | 8.38 M | ||||
| Current Liabilities | 721.01 K | ||||
| Net Asset | 57 M |
About INmune Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze INmune Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of INmune Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of INmune Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out INmune Bio Piotroski F Score and INmune Bio Altman Z Score analysis. For information on how to trade INmune Stock refer to our How to Trade INmune Stock guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Complementary Tools for INmune Stock analysis
When running INmune Bio's price analysis, check to measure INmune Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy INmune Bio is operating at the current time. Most of INmune Bio's value examination focuses on studying past and present price action to predict the probability of INmune Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move INmune Bio's price. Additionally, you may evaluate how the addition of INmune Bio to your portfolios can decrease your overall portfolio volatility.
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios |
Is INmune Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of INmune Bio. If investors know INmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about INmune Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.67) | Revenue Per Share 0.009 | Quarterly Revenue Growth (0.71) | Return On Assets (0.27) | Return On Equity (0.61) |
The market value of INmune Bio is measured differently than its book value, which is the value of INmune that is recorded on the company's balance sheet. Investors also form their own opinion of INmune Bio's value that differs from its market value or its book value, called intrinsic value, which is INmune Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because INmune Bio's market value can be influenced by many factors that don't directly affect INmune Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between INmune Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if INmune Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, INmune Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.